Sutro Biopharma Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Sutro Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $48.31. The average 1-year stock price forecast is 70.05% higher than the current stock price, while the lowest is $10 (-64.80%) and the highest is $61 (+114.71%).

Price Target: $48.31 (+70.05%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$48.31	$50	$61
Change	-64.80%	+70.05%	+75.99%	+114.71%

Analyst Ratings

The average analyst rating for Sutro Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	6	8	9	10
Buy	2	2	2	2	2	2
Hold	3	3	1	1	0	0
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	10	10	10	12	12	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Supawat Thongthip Truist Financial	Truist Financial	Buy Initiates $50	Buy	Initiates	$50	+75.99%	Jun 11, 2026
Charles Zhu LifeSci Capital	LifeSci Capital	Buy Maintains $54	Buy	Maintains	$54	+90.07%	May 30, 2026
Lukas Shumway Barclays	Barclays	Buy Initiates $56	Buy	Initiates	$56	+97.11%	May 28, 2026
Andres Y. Maldonado H.C. Wainwright	H.C. Wainwright	Buy Maintains $50	Buy	Maintains	$50	+75.99%	May 26, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Sell Reiterates n/a	Sell	Reiterates	n/a	n/a	May 22, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

45.06M

from 102.48M

-56.03%

from 102.48M

Revenue Next Year

32.22M

from 45.06M

-28.50%

from 45.06M

EPS This Year

-7.80

from -16.20

EPS Next Year

-6.89

from -7.80

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	61.88M	67.77M	153.73M	62.04M	102.48M	45.06M
Revenue Growth	44.84%	9.52%	126.84%	-59.64%	65.18%	-56.03%
Gross Profit	-42.52M	-69.40M	-26.69M	-190.00M	-63.93M	45.06M
Gross Margin	-68.71%	-102.40%	-17.36%	-306.24%	-62.38%	100.00%
Operating Income	-98.52M	-128.94M	-89.28M	-238.45M	-104.95M	-119.76M
Net Income	-105.54M	-119.20M	-106.79M	-227.46M	-191.09M	-137.65M
EPS	-	-	-	-	-16.20	-7.80
Free Cash Flow	-59.62M	-41.16M	-36.57M	-78.99M	-112.39M	-102.77M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	69.2M
Avg	45.1M
Low	14.5M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-32.5%
Avg	-56.0%
Low	-85.9%

EPS Forecast

EPS	2026	2027	2028
High	-7.30
Avg	-7.80
Low	-8.31

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-